Compare Occidental Petroleum Corporation (OXY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Occidental Petroleum Corporation vs TG Therapeutics Inc — how do they compare? Occidental Petroleum Corporation trades at $61.52 (market cap $61.28B), while TG Therapeutics Inc trades at $54.77 (market cap $8.36B). The key difference: Occidental Petroleum Corporation is far larger — about 7.3× TG Therapeutics Inc's market cap, and Occidental Petroleum Corporation pays a 1.83% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| OXY | TGTX | |
|---|---|---|
Market Cap | $61.28B | $8.36B |
Sector | Energy | Health |
52-Week High | $66.24 | $59.06 |
52-Week Low | $38.92 | $26.94 |
Enterprise Value | $80.04B | $8.57B |
Dividend Yield | 1.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Occidental Petroleum (OXY) trades at $60.65, up 1.02% today, with a bullish technical signal from moving averages and a consensus analyst price target of $68.67. The company has beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.40 surpassing expectations of $1.83. Financials show strong profitability with a 30.32% net income margin and robust cash flow from operations of $10.53 billion in 2025, though revenue has declined from $36.6 billion in 2022 to $21.6 billion in 2025.
OXY presents a positive outlook with debt reduction progress and projected net income margin rebound to 30.31% in 2026. Investment opportunities include potential upside to the price target and sustainable cash flow growth. Risks include oil price volatility, geopolitical tensions affecting energy markets, and execution challenges in maintaining profitability amid fluctuating revenues.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
